Hospital
ST Francis Regional Medical Center
ST Francis Regional Medical Center was paid $13.03M by Medicaid between Jan 2018 and Dec 2024, across 65 billing codes. Its largest line is 99284, emergency room visit (serious) — 46% of everything it billed.
33Billing provider infoST FRANCIS REGIONAL MEDICAL CENTER
SHAKOPEE, MN 55379
SHAKOPEE, MN 55379
33aNPI1578520045assigned 04/28/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$13.03M
24GClaims143,670
24DCodes billed65
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Minnesota
Rank by total paid#17 of 36
Median peer was paid$11.46M
This provider vs. median1.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,697 | $956K | |
| 2019 | 15,067 | $1.65M | |
| 2020 | 13,720 | $1.16M | |
| 2021 | 25,884 | $1.98M | |
| 2022 | 27,470 | $2.46M | |
| 2023 | 26,034 | $2.58M | |
| 2024incomplete | 17,798 | $2.24M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 46% | 20,815 | 20,074 | $5.93M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 33% | 23,335 | 22,583 | $4.28M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 5.6% | 14,406 | 13,571 | $727K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.6% | 3,453 | 3,298 | $336K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.6% | 1,708 | 1,690 | $214K |
| 80053 | Comprehensive metabolic panel | 1.5% | 5,549 | 5,252 | $199K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 18,270 | 17,221 | $186K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 5,136 | 4,473 | $180K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 2,342 | 2,076 | $160K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.0% | 6,816 | 6,380 | $133K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,640 | 1,561 | $93K |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,469 | 12,726 | $90K |
53 more codes
| 99285 | Emergency room visit (most serious) | <1% | 209 | $86K |
| 85027 | <1% | 4,002 | $71K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 799 | $44K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,225 | $26K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 189 | $23K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 330 | $23K |
| 71045 | Radiologic examination, chest; single view | <1% | 251 | $20K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 342 | $18K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 39 | $17K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 753 | $16K |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 26 | $14K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,243 | $13K |
| 81001 | <1% | 1,006 | $12K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 208 | $11K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,422 | $11K |
| D2393 | Resin-based composite - three surfaces, posterior, primary or permanent | <1% | 12 | $10K |
| 83690 | <1% | 1,285 | $7K | |
| 84484 | <1% | 1,232 | $7K | |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 29 | $7K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,516 | $7K |
| 82248 | <1% | 1,277 | $6K | |
| J2704 | Injection, propofol, 10 mg | <1% | 877 | $6K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 24 | $6K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 466 | $5K |
| 87081 | <1% | 379 | $4K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 52 | $4K |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 3,584 | $3K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 40 | $3K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 40 | $3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 158 | $3K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 89 | $2K |
| 84703 | <1% | 201 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 115 | $1K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 41 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 297 | $1K |
| 84512 | <1% | 54 | $873.66 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 233 | $805.74 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 150 | $679.65 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 13 | $489.49 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 110 | $455.72 |
| 84145 | <1% | 14 | $436.51 | |
| 83605 | <1% | 68 | $401.24 | |
| 81025 | <1% | 52 | $385.90 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 38 | $346.04 |
| 86803 | <1% | 13 | $301.00 | |
| 80061 | Lipid panel | <1% | 13 | $253.86 |
| 81003 | <1% | 46 | $196.61 | |
| 87807 | <1% | 12 | $159.72 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 38 | $158.58 |
| 86140 | <1% | 14 | $124.35 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 76 | $53.53 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 17 | $45.25 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJERDEE, AMY (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| ST. Francis Regional Medical Center | Shakopee, MN | $1.21M |
| ST Francis Regional Medical Center | Jordan, MN | $155K |
| ST Francis Regional Medical Center | Shakopee, MN | $44K |
| ST Francis Regional Medical Center | Shakopee, MN | $22K |
| ST Francis Regional Medical Center | Savage, MN | $10K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.